

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicenter phase II study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028056
Article Type:	Protocol
Date Submitted by the Author:	20-Nov-2018
Complete List of Authors:	<p>Iihara, Hirotoishi; Gifu University Hospital, Department of Pharmacy,; Gifu Pharmaceutical University, Laboratory of Pharmacy Practice and Social Science</p> <p>Shimokawa, Mototsugu; Clinical Research Institute, National Hospital Organization Kyusyu Cancer Center, Cancer Biostatistics Laboratory</p> <p>Gomyo, Takenobu; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respiriology</p> <p>Fujita, Yukiyoishi; Gunma Prefectural Cancer Center, Division of Pharmacy</p> <p>Yoshida, Tsutomu; Gifu Municipal Hospital, Department of Respiratory Medicine and Medical Oncology</p> <p>Funaguchi, Norihiko; Asahi University Hospital, Department of Respiratory Medicine</p> <p>Minato, Koichi; Gunma Prefectural Cancer Center, Division of Respiratory Medicine</p> <p>Kaito, Daizo; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respiriology</p> <p>Osawa, Tomohiro; Gifu Municipal Hospital, Department of Pharmacy</p> <p>Yamada, Momoko; Asahi University Hospital, Department of Pharmacy</p> <p>Hirose, Chiemi; Gifu University Hospital, Department of Pharmacy</p> <p>Suzuki, Akio; Gifu University Hospital, Department of Pharmacy</p> <p>Ohno, Yasushi; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respiriology</p>
Keywords:	olanzapine, carboplatin, nausea, vomiting

SCHOLARONE™
Manuscripts

1
2
3
4 Doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with
5
6
7 thoracic cancer: a multicenter phase II study protocol
8
9

10
11
12
13 Short title: Olanzapine for carboplatin-induced CINV
14
15
16

17
18
19 Hirotohi Iihara^{1,2}, Mototsugu Shimokawa³, Takenobu Gomyo⁴, Yukiyoishi Fujita⁵, Tsutomu
20
21
22 Yoshida⁶, Norihiko Funaguchi^{4,7}, Koichi Minato⁸, Daizo Kaito⁴, Tomohiro Osawa⁹, Momoko
23
24
25 Yamada¹⁰, Chiemi Hirose¹, Akio Suzuki¹, Yasushi Ohno⁴
26
27
28
29
30

31 **Author affiliations:**
32
33

34 ¹Department of Pharmacy, Gifu University Hospital, Gifu, Japan
35
36

37 ²Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu,
38
39
40 Japan
41
42

43 ³Cancer Biostatistics Laboratory, National Hospital Organization Kyusyu Cancer Center,
44
45
46 Fukuoka, Japan
47
48

49 ⁴Department of Cardiology and Respiriology, Gifu University Graduate School of Medicine,
50
51
52 Gifu, Japan
53
54

55 ⁵Division of Pharmacy, Gunma Prefectural Cancer Center, Gunma, Japan
56
57

58 ⁶Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Gifu,
59
60

1
2
3
4 Japan

5
6
7 ⁷Department of Respiratory Medicine, Asahi University Hospital, Gifu, Japan

8
9
10 ⁸Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan

11
12
13 ⁹Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan

14
15
16 ¹⁰Department of Pharmacy, Asahi University Hospital, Gifu, Japan

17
18
19
20
21
22 **Corresponding author:**

23
24
25 Hirotoshi Iihara

26
27
28 1-1 Yanagido, Gifu, 501-1194, Japan

29
30
31 Phone: +81-58-230-7088

32
33
34 Fax number: +81-58-230-7084

35
36
37 E-mail address: dai0920@gifu-u.ac.jp

ABSTRACT

Introduction: Adding neurokinin-1 receptor antagonist (NK₁RA) to 5-hydroxytryptamine-3 receptor antagonist and dexamethasone (DEX) improved carboplatin (CBDCA) -induced chemotherapy-induced nausea and vomiting (CINV) in patients with thoracic cancer.

NK1RAs with high drug cost are raising medical expenses. Olanzapine (OLZ) is less expensive and can be expected to have an excellent effect on CINV. This phase II trial aimed to evaluate the efficacy and safety of 5 mg olanzapine plus granisetron (GRN) and DEX in CBDCA combination therapy with AUC \geq 5 mg/mL/min for the prevention of nausea and vomiting in patients with thoracic cancer.

Methods and analysis: This is open-label, single-arm, multicenter, phase II trial. Patients who receive carboplatin (AUC \geq 5)-based therapy and have never been administered moderate to high emetogenic chemotherapy will be enrolled. All patients will receive combination of GRA, DEX, and OLZ. The primary endpoint was complete response (CR) rate, defined as the absence of emetic episodes and no use of rescue medication during 120 h after the initiation of CBDCA. Forty-eight patients were required based on our hypothesis that this regimen can improve CR rate from 65% (null hypothesis) to 80% (alternative hypothesis) with a one-sided type I error of 0.1 and a power of 0.8. We set the target sample size at 50 considering the dropout rate.

Ethics and dissemination: The study protocol was approved by the institutional review board

1
2
3
4 at each of the participating centers. Data will be presented at international conferences and
5
6
7 published in peer-reviewed journals.
8
9

10 **Trial registration:** This study protocol was registered at the UMIN Clinical Trial Registry as
11
12
13 UMIN000031267.
14
15
16
17

18
19 Key words: olanzapine, carboplatin, nausea, vomiting
20
21
22
23
24

25 **Strengths and limitations of this study**

- 26 ● This is a first trial to evaluate efficacy and safety of adding 5 mg olanzapine to
27
28 granisetron and dexamethasone for CINV after $AUC \geq 5$ mg/mL/min CBDCA
29
30
31 combination therapy in thoracic cancer patients.
32
33
34
- 35 ● A positive result of this phase II trial is necessary before a phase III trial can be
36
37
38 conducted. The data will be used to inform a future large multicenter double-blind
39
40
41
42 randomized phase III trial.
43
44
- 45 ● Limitations are open-label and single arm design.
46
47
48
49
50

51 **INTRODUCTION**

52
53
54 Carboplatin (CBDCA) administered to achieve an area under the blood concentration-time
55
56
57 curve (AUC) of ≥ 4 mg/mL/min is ranked as the highest risk drug among the moderately
58
59
60

1
2
3
4 emetogenic chemotherapy (MEC) agents and/or the highly emetogenic chemotherapy (HEC).
5
6
7 The American Society of Clinical Oncology (ASCO) [1], the Multinational Association of
8
9
10 Supportive Care in Cancer (MASCC) [2], and the National Comprehensive Cancer Network
11
12
13 (NCCN) [3] have recommended emesis prophylaxis using a three-drug combination therapy
14
15
16 including 5-hydroxytryptamine-3 receptor antagonist (5-HT₃RA), dexamethasone (DEX), and
17
18
19 neurokinin-1 receptor antagonist (NK₁RA).
20
21

22 CBDCA is widely used against various cancers. The complete response (CR) rate (the
23
24
25 absence of emetic episodes and no use of rescue medication) for first generation 5-HT₃RA
26
27
28 and DEX varies depending on the cancer type; the rate is approximately 50% in patients with
29
30
31 gynecological cancer [4-5] and approximately 65% in those with thoracic cancer [6-7]. This
32
33
34 difference is due to the background of cancer types. Gynecological cancer patients are only
35
36
37 females and are younger than thoracic cancer. Female gender, younger age, non-habitual
38
39
40 alcohol intake and non-smoker etc. are known as risk factors for chemotherapy-induced
41
42
43 nausea and vomiting (CINV) [8]. Therefore, we believe NK₁RA with high drug cost is
44
45
46 unnecessary for carboplatin-based therapy in thoracic cancer patients.
47
48

49 Olanzapine (OLZ) is classified as a multi-acting receptor-targeted antipsychotic and blocks
50
51
52 dopaminergic D₁, D₂, D₃, and D₄ receptors; serotonergic 5-HT_{2A}, 5-HT_{2B}, 5-HT₃, and 5-HT₆
53
54
55 receptors; histamine H₁ receptors; and muscarinic acetylcholine M₁, M₂, M₃, and M₄ receptors
56
57
58 [9]. Among its other uses, OLZ is used to improve CINV. Navari et al. reported that 10mg
59
60

1
2
3
4 OLZ combined with palonosetron (PALO) and DEX has an equivalent antiemetic effect to an
5
6
7 antiemetic regimen consisting of PALO, DEX, and aprepitant (APR), in CR rate, and
8
9
10 excellent in control of nausea in highly emetogenic chemotherapy (HEC) [10]. Moreover, in
11
12
13 Europe and the United States, the effectiveness of a combination of 10 mg OLZ and standard
14
15
16 antiemetic therapy has been demonstrated for HEC in randomized control trials; however, the
17
18
19 resulting patient sedation due to the therapy may be a concern [11-14]. In Japan, three phase II
20
21
22 studies revealed the efficacy and safety of the combination of 5 mg OLZ and standard triplet
23
24
25 therapy for CINV induced by HEC [15-17]. In a trial, Yanai et al. reported that OLZ at 5 mg
26
27
28 and 10 mg showed comparable CR effects, but the 5 mg dose was less sedative [17].
29

30
31 However, the effectiveness of OLZ against CBDCA-induced CINV has not been
32
33
34 demonstrated. The cost per treatment cycle of 5 mg of OLZ (brand: 733.60 JPY, generic:
35
36
37 180.80 JPY) is less than that of PALO (14851.00 JPY) or NK₁RA (APR: 11638.20 JPY,
38
39
40 fosaprepitant: 14545.00 JPY), and confirming the effectiveness of the combination use of
41
42
43 OLZ, first generation 5-HT₃RA, and DEX would change the standard antiemetic treatment for
44
45
46 CBDCA-based chemotherapy in thoracic cancer. We planned this open-label, single-arm,
47
48
49 multicenter, phase II trial to evaluate the efficacy and safety of 5 mg olanzapine plus
50
51
52 granisetron (GRN) and DEX in CBDCA combination therapy with AUC \geq 5 mg/mL/min for
53
54
55 the prevention of CINV in patients with thoracic cancer.
56
57
58
59
60

Study Protocol

Objective

Our objective was to evaluate the efficacy and safety of 5 mg olanzapine plus GRA and DEX for the prevention of nausea and vomiting during CBDCA combination therapy achieving $AUC \geq 5$ mg/mL/min in patients with thoracic cancer. The study was approved by the institutional review board at each participating center and was independently monitored by the alliance data center and safety monitoring board.

Study setting

This study was an open-label, single-arm, multicenter, phase II trial conducted in four centers in Japan.

End points

We chose the CR rate as the primary endpoint, defined as the absence of emetic episodes and no use of rescue medication during the overall assessment period (0–120 h) after the initiation of CBDCA.

Secondary endpoints were the CR rate at the early assessment period (0–24 h), the CR rate at the delayed assessment period (25–120 h), and the complete control rate (defined as the

1
2
3
4 absence of nausea and emetic episodes and no use of rescue medication during the overall
5
6
7 assessment period). We used a four-grade categorical scale (none, mild, moderate, or severe)
8
9
10 to stratify nausea and chose the moderate and severe categories to define significant nausea.
11
12
13 The total control rate was defined as the absence of nausea and emetic episodes and no use of
14
15
16 rescue medication for the acute, delayed, and assessment periods. The time to treatment
17
18
19 failure was defined as the time to the first emetic episode or the use of rescue medication.
20
21
22 Severity has been classified into a four-grade categorical scale, including nausea, anorexia,
23
24
25 sleepiness, and the impact on life. Patient satisfaction with antiemetic therapy.
26
27
28
29
30

31 Adverse events were graded according to the CTCAE version 4.0.
32
33
34
35
36

37 **Eligibility criteria**

38 **Inclusion criteria**

- 39
40
41
42
43 (i) Patients with thoracic cancer scheduled to receive carboplatin-based chemotherapy (AUC
44
45
46 ≥ 5)
47
48
49 (ii) Age, 20–79 years at registration
50
51
52 (iii) Eastern Cooperative Oncology Group performance status of 0, 1, or 2
53
54
55 (iv) Absence of symptomatic brain metastasis and carcinomatosis
56
57
58 (v) Absence of a history of the administration of moderate-to-high emetogenic chemotherapy
59
60

1
2
3
4 (vi) No current use of any drug with antiemetic activity or inducing somnolence, such as
5
6
7 5-HT₃RA, NK₁RA, corticosteroids, dopamine receptor antagonists, phenothiazine
8
9
10 tranquilizers, antihistamine drugs (paclitaxel administration allowed during premedication),
11
12
13 and benzodiazepine agents

14
15
16 (vii) Meeting the following standard values of general clinical tests:

17
18
19 (a) aspartate aminotransferase ≤ 100 U/L

20
21
22 (b) alanine aminotransferase ≤ 100 U/L

23
24
25 (c) total bilirubin ≤ 2.0 mg/dL

26
27
28 (viii) Patients who provided written informed consent

29
30
31
32
33
34 **Exclusion criteria**

35
36
37 (i) History of hypersensitivity or allergy to study drugs or similar compounds

38
39
40 (ii) Antiemetics needed at the time of enrollment

41
42
43 (iii) Started opioid intake in the 48 h prior to enrollment

44
45
46 (iv) Presence of unstable angina, ischemic heart disease, cerebral hemorrhage or apoplexy, or
47
48 active gastric or duodenal ulcer within 6 months prior to enrollment

49
50
51 (v) Presence of convulsive disorders requiring anticonvulsants therapy

52
53
54 (vi) Presence of ascites effusion requiring paracentesis

55
56
57 (vii) Presence of gastrointestinal obstruction

1
2
3
4 (viii) Breastfeeding or pregnant women or those not willing to use contraception
5
6

7 (ix) Presence of psychosis or psychiatric symptoms that interfere with daily life
8
9

10 (x) Abdominal or pelvic irradiation within 6 d prior to enrollment
11
12

13 (xi) Presence of diabetes mellitus
14
15

16 (xii) Being a habitual smoker at the time of enrollment
17
18

19 (xiii) Patients deemed inappropriate for the study by the investigator
20
21
22
23
24

25 **Registration**

26
27
28 The accrual started in February 2018.
29
30
31
32
33

34 **Treatment methods**

35
36
37 All patients received GRA (1 mg intravenous infusion on day 1, 30 min before
38
39 chemotherapy), DEX (9.9 mg intravenous infusion or 12 mg oral administration on day 1, 30
40
41 min before chemotherapy, and 6.6 mg intravenous infusion or 8 mg oral administration on
42
43 days 2–3), and OLZ (5 mg oral administration on days 1–4, after supper). In addition, when
44
45 paclitaxel was used, DEX was administered at 19.8 mg intravenously or 20 mg orally on day
46
47
48
49
50
51

52 1.
53
54
55
56
57

58 **Follow up**

59
60

1
2
3
4 We scheduled physical and blood examinations of patients before the initiation of treatment
5
6
7 and once between days 5 and 15 after treatment initiation. The data are collected from patient
8
9
10 diaries. Patients are required to fill the diary for every 24 h from the start of chemotherapy to
11
12
13 120 h periods. After the overall assessment period (0–120 h), patient-reported study diaries
14
15
16 were collected (figure 1. provides details of the schedule of enrolment, interventions, and
17
18
19 assessments).

25 **Study design and statistical methods**

26
27
28 The hypothesis of this study was that the CR rate for 5 mg olanzapine plus GRA and DEX
29
30 during CBDCA combination therapy achieving $AUC \geq 5$ mg/mL/min would be significantly
31
32
33 higher than that for standard antiemetic doublet therapy.
34
35

36
37 Other trials have shown CR rates of approximately 65% [6, 7]. An improvement of the
38
39
40 treatment effect has to be >10% to amend the guideline of the MASCC/ESMO2016 [2]
41
42
43 according to previous studies in which the CR ratio of antiemesis treatment by PALO, DEX,
44
45
46 and APR was 80.5%–92% [18–20]. We think an improvement of >15% in the CR rate can be
47
48
49 clinically meaningful.

50
51
52 Therefore, assuming a null hypothesis of the CR rate to be $\leq 65\%$ and an alternative
53
54
55 hypothesis to be 80%, we calculated that a minimum of 48 patients are required to achieve a
56
57
58 one-sided type I error of 0.1 and 80% of power based on the exact binomial distribution.
59
60

1
2
3
4 Because some dropouts are expected, we set the target sample size at 50.
5
6
7
8
9

10 **Patient and Public Involvement**

11
12
13 Patients and/or public were not involved in the design of this study.
14
15
16
17

18 **Ethics and dissemination**

19
20
21
22 The study protocol was approved by the institutional review board at each of the participating
23
24
25 centers. Data will be presented at international conferences and published in peer-reviewed
26
27
28 journals.
29
30
31
32
33

34 **University hospital medical information network (UMIN) registration**

35
36
37 This study protocol was registered at the UMIN Clinical Trial Registry (UMIN-CTR) on
38
39
40 February 14, 2018, as UMIN000031267 (<http://www.umin.ac.jp/ctr/index-j.htm>).
41
42
43
44
45

46 **Participating institutions**

47
48
49 Gifu University Hospital, Gifu Municipal Hospital, Murakami Memorial Hospital Asahi
50
51
52 University, and Gunma Prefectural Cancer Center.
53
54
55
56
57

58 **Funding statement**

1
2
3
4 This work was supported by self-funding from the Department of Cardiology and Respiriology
5
6
7 at the Gifu University Graduate School of Medicine.
8
9

10 **Competing interests statement**

11
12
13 None declared.
14
15
16
17
18

19 **Authors' contributions**

20
21
22 HI, MS, TG, YF, and YO made a significant contribution to the conception and design of the
23
24
25 study protocol. MS provided statistical expertise. The protocol was written by HI, MS, TG,
26
27
28 YF, TY, NF, KM, DK, TO, MY, and CH and critically reviewed by AS, and YO. HI, MS,
29
30
31 TG, and YF drafted the manuscript. All the authors read and approved the final paper.
32
33
34
35
36

37 **References**

- 38
39
40 1. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical
41
42
43 Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017;35:3240–61.
44
45
46 2. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for
47
48
49 the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of
50
51
52 nausea and vomiting in advanced cancer patients. *Ann Oncol* 2016;27 Suppl 5:v119–33.
53
54
55 3. NCCN clinical practice guidelines in oncology: Antiemesis Version 2.2017. Available
56
57
58 from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
59
60

- 1
2
3
4 4. Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebo-controlled, double-blind
5
6
7 study of aprepitant in nondrinking women younger than 70 years receiving moderately
8
9
10 emetogenic chemotherapy. *Br J Cancer* 2013;109:859–65.
11
- 12
13 5. Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of
14
15
16 chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy
17
18
19 regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients
20
21
22 with gynecologic cancer receiving paclitaxel and carboplatin. *Int J Clin Oncol*
23
24
25 2016;21:491–7.
26
- 27
28 6. Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell
29
30
31 lung cancer receiving carboplatin-based chemotherapy. *Lung Cancer* 2014; 84:259–64.
32
- 33
34 7. Endo J, Iihara H, Yamada M, et al. A randomized controlled non-inferiority study
35
36
37 comparing the antiemetic effect between intravenous granisetron and oral azasetron based
38
39
40 on estimated 5-HT₃ receptor occupancy. *Anticancer Res* 2012;32:3939–47.
41
- 42
43 8. Sekine I, Segawa Y, Kubota K, et al. Risk factors of chemotherapy-induced nausea and
44
45
46 vomiting: index for personalized antiemetic prophylaxis. *Cancer Sci* 2013; 104:711–7.
47
- 48
49 9. Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced
50
51
52 nausea and vomiting. *J Adv Pract Oncol* 2014;5:24–9.
53
- 54
55 10. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of
56
57
58 chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J Support*
59
60

- 1
2
3
4 Oncol 2011;9:188–95.
5
6
7 11. Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant
8
9
10 for the prevention of concurrent chemotherapy radiotherapy-induced nausea and
11
12
13 vomiting. *J Community Support Oncol* 2016;14:141–7.
14
15
16 12. Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriappa L, et al. The efficacy, safety,
17
18
19 and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: A
20
21
22 pilot study from south India. *Chemother Res Pract* 2016;2016:3439707.
23
24
25 13. Wang X, Wang L, Wang H, Zhang H. Effectiveness of olanzapine combined with
26
27
28 ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small
29
30
31 cell lung cancer. *Cell Biochem Biophys* 2015;72:471–3.
32
33
34 14. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of
35
36
37 chemotherapy-induced nausea and vomiting. *N Engl J Med* 14;375:134–42.
38
39
40 15. Abe M, Hirashima Y, Kasamatsu Y, et al. Efficacy and safety of olanzapine combined
41
42
43 with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting
44
45
46 induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase
47
48
49 II trial. *Support Care Cancer* 2016;24:675–82.
50
51
52 16. Nakashima K, Murakami H, Yokoyama K, et al. A Phase II study of palonosetron,
53
54
55 aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based
56
57
58 chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. *Jpn J*
59
60

- 1
2
3
4 Clin Oncol 2017;47:840–3.
5
6
7 17. Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding
8
9 study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly
10
11
12
13 emetogenic cisplatin-based chemotherapy. *Int J Clin Oncol* 2018; 23:382–8.
14
15
16 18. Kitazaki T, Fukuda Y, Fukahori S, et al. Usefulness of antiemetic therapy with aprepitant,
17
18
19 palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or
20
21
22 carboplatin-based chemotherapy. *Support Care Cancer* 2015; 23:185–90.
23
24
25 19. Kusagaya H, Inui N, Karayama M, et al. Evaluation of palonosetron and dexamethasone
26
27
28 with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients
29
30
31 with advanced non-small-cell lung cancer. *Lung Cancer* 2015; 90:410–6.
32
33
34 20. Miya T, Kobayashi K, Hino M, et al. Efficacy of triple antiemetic therapy (palonosetron,
35
36
37 dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients
38
39
40 receiving carboplatin-based, moderately emetogenic chemotherapy. *Springerplus* 2016;
41
42
43 5:2080.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Antiemetic administrations

Antiemetics		day1	day2	day3	day4
granisetron	i.v.	1mg			
dexamethasone	p.o.	12mg*	8mg	8mg	
	or				
dexamethasone	i.v.	9.9mg*	6.6mg	6.6mg	
olanzapine	p.o.	5mg	5mg	5mg	5mg

*When paclitaxel is used, on day 1 DEX is administered 19.8 mg intravenously or 20 mg orally.

Figure 1. The schedule of enrolment, interventions, and assessments

	Enrolment	Enrolment	Post- Enrolment					
TIMEPOINT	-8 days	0	day1	day2	day3	day4	day5	day6
ENROLMENT:								
Eligibility screen	X							
History and physical	X							
ECOG PS	X							
Laboratory studies	X							X
Informed consent	X							
Enrolment		X						
INTERVENTIONS:								
<i>Antiemetic administrations</i>			←————→					
ASSESSMENTS:								
<i>Patient diaries</i>		X	X	X	X	X	X	X
<i>Adverse events</i>		X	X	X	X	X	X	X
<i>Patient related factor survey</i>								X
<i>Patient satisfaction</i>								X



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	12
	2b	All items from the World Health Organization Trial Registration Data Set	12
Protocol version	3	Date and version identifier	12
Funding	4	Sources and types of financial, material, and other support	12
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	13
	5b	Name and contact information for the trial sponsor	1, 13
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	none
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	7

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 5, 6
4 rationale studies (published and unpublished) examining benefits and harms for each intervention
5

6 6b Explanation for choice of comparators 11
7

8 Objectives 7 Specific objectives or hypotheses 7
9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 7
11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
12
13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 12
17 be collected. Reference to where list of study sites can be obtained
18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 8, 9
20 individuals who will perform the interventions (eg, surgeons, psychotherapists)
21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 10
23 administered
24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 10, 11
26 change in response to harms, participant request, or improving/worsening disease)
27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 10, 11
29 (eg, drug tablet return, laboratory tests)
30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 10, 11
32

33 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
34 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 7, 8
35 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
36 efficacy and harm outcomes is strongly recommended
37

38 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 18
39 participants. A schematic diagram is highly recommended (see Figure)
40
41
42

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	12
5				

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	single arm
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	single arm
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	single arm
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	non- blinded
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	non- blinded
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	17
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	10, 11
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	no plans
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	7
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	no interim analysis
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	10, 11
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	no plans
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	12
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	12
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	no plans
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	7
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	none
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	12
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	13
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	none
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	9
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	none
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 “[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)” license.
 40
 41
 42

BMJ Open

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicenter phase II trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028056.R1
Article Type:	Protocol
Date Submitted by the Author:	17-May-2019
Complete List of Authors:	Iihara, Hirotooshi; Gifu University Hospital, Department of Pharmacy,; Gifu Pharmaceutical University, Laboratory of Pharmacy Practice and Social Science Shimokawa, Mototsugu; Clinical Research Institute, National Hospital Organization Kyusyu Cancer Center, Cancer Biostatistics Laboratory Gomyo, Takenobu; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respirology Fujita, Yukiyooshi; Gunma Prefectural Cancer Center, Division of Pharmacy Yoshida, Tsutomu; Gifu Municipal Hospital, Department of Respiratory Medicine and Medical Oncology Funaguchi, Norihiko; Asahi University Hospital, Department of Respiratory Medicine Minato, Koichi; Gunma Prefectural Cancer Center, Division of Respiratory Medicine Kaito, Daizo; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respirology Osawa, Tomohiro; Gifu Municipal Hospital, Department of Pharmacy Yamada, Momoko; Asahi University Hospital, Department of Pharmacy Hirose, Chiemi; Gifu University Hospital, Department of Pharmacy Suzuki, Akio; Gifu University Hospital, Department of Pharmacy Ohno, Yasushi; Gifu University School of Medicine Graduate School of Medicine, Department of Cardiology and Respirology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Oncology
Keywords:	olanzapine, carboplatin, nausea, vomiting

SCHOLARONE™
Manuscripts

1
2
3
4 Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and
5
6
7 vomiting in patients with thoracic cancer: a multicenter phase II trial
8
9

10
11
12
13 Short title: Olanzapine for carboplatin-induced CINV
14
15
16

17
18
19 Hirotohi Iihara^{1,2}, Mototsugu Shimokawa³, Takenobu Gomyo⁴, Yukiyoishi Fujita⁵, Tsutomu
20
21
22 Yoshida⁶, Norihiko Funaguchi^{4,7}, Koichi Minato⁸, Daizo Kaito⁴, Tomohiro Osawa⁹, Momoko
23
24
25 Yamada¹⁰, Chiemi Hirose¹, Akio Suzuki¹, Yasushi Ohno⁴
26
27
28
29
30

31 **Author affiliations:**
32
33

34 ¹Department of Pharmacy, Gifu University Hospital, Gifu, Japan
35
36

37 ²Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu,
38
39
40 Japan
41
42

43 ³Cancer Biostatistics Laboratory, National Hospital Organization Kyusyu Cancer Center,
44
45
46 Fukuoka, Japan
47
48

49 ⁴Department of Cardiology and Respirology, Gifu University Graduate School of Medicine,
50
51
52 Gifu, Japan
53
54

55 ⁵Division of Pharmacy, Gunma Prefectural Cancer Center, Gunma, Japan
56
57

58 ⁶Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Gifu,
59
60

1
2
3
4 Japan

5
6
7 ⁷Department of Respiratory Medicine, Asahi University Hospital, Gifu, Japan

8
9
10 ⁸Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan

11
12
13 ⁹Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan

14
15
16 ¹⁰Department of Pharmacy, Asahi University Hospital, Gifu, Japan

17
18
19
20
21
22 **Corresponding author:**

23
24
25 Hirotooshi Iihara

26
27
28 1-1 Yanagido, Gifu, 501-1194, Japan

29
30
31 Phone: +81-58-230-7088

32
33
34 Fax number: +81-58-230-7084

35
36
37 E-mail address: dai0920@gifu-u.ac.jp

ABSTRACT

Introduction: Adding neurokinin-1 receptor antagonist (NK₁RA) to 5-hydroxytryptamine-3 receptor antagonist and dexamethasone (DEX) improved carboplatin (CBDCA) -induced chemotherapy-induced nausea and vomiting (CINV) in patients with thoracic cancer.

NK1RAs with high drug cost are raising medical expenses. Olanzapine (OLZ) is less expensive and can be expected to have an excellent effect on CINV. This phase II trial aimed to evaluate the efficacy and safety of 5 mg olanzapine plus granisetron (GRN) and DEX in CBDCA combination therapy with AUC \geq 5 mg/mL/min for the prevention of nausea and vomiting in patients with thoracic cancer.

Methods and analysis: This is an open-label, single-arm, multicenter, phase II trial. Patients who receive CBDCA (AUC \geq 5)-based therapies and have never been administered moderate to high emetogenic chemotherapy will be enrolled. All patients will receive a combination of GRA, DEX, and OLZ. The primary endpoint is complete response (CR) rate, defined as the absence of emetic episodes and no use of rescue medication during 120 h after the initiation of CBDCA. Forty-eight patients are required based on our hypothesis that this regimen can improve CR rate from 65% (null hypothesis) to 80% (alternative hypothesis) with a one-sided type I error of 0.1 and a power of 0.8. We set the target sample size at 50 considering the dropout rate.

Ethics and dissemination: The study protocol was approved by the institutional review board

1
2
3
4 at each of the participating centers. Data will be presented at international conferences and
5
6
7 published in peer-reviewed journals.
8
9

10 **Trial registration:** This study protocol was registered at the UMIN Clinical Trial Registry as
11
12
13 UMIN000031267.
14
15
16
17

18
19 Key words: olanzapine, carboplatin, nausea, vomiting
20
21
22
23
24

25 **Strengths and limitations of this study**

- 26 ● This is a first trial to evaluate efficacy and safety of adding 5 mg olanzapine to
27
28 granisetron and dexamethasone for CINV after $AUC \geq 5$ mg/mL/min CBDCA
29
30
31 combination therapy in thoracic cancer patients.
32
33
34
- 35 ● A positive result of this phase II trial is necessary before a phase III trial can be
36
37 conducted. The data will be used to inform a future large multicenter double-blind
38
39
40 randomized phase III trial.
41
42
43
- 44 ● Limitations are open-label and single arm design. And the study is conducted within the
45
46 Japanese population.
47
48
49
50

51 **INTRODUCTION**

52
53
54 In recent guidelines, carboplatin (CBDCA) is reclassified at the upper limit of the
55
56 moderately emetogenic chemotherapy (MEC) category and/or the highly emetogenic
57
58
59
60

1
2
3
4 chemotherapy (HEC) [1-3]. The Multinational Association of Supportive Care in Cancer
5
6 (MASCC) (regardless of the CBDCA dose) [1], the American Society of Clinical Oncology
7
8 (ASCO) (CBDCA at a dose of ≥ 4 mg/mL/min) [2], and the National Comprehensive Cancer
9
10
11
12 Network (NCCN) (CBDCA at a dose of ≥ 4 mg/mL/min) [3] have recommended emesis
13
14
15 prophylaxis using a three-drug regimen including 5-hydroxytryptamine-3 receptor antagonist
16
17
18 (5-HT₃RA), dexamethasone (DEX), and neurokinin-1 receptor antagonist (NK₁RA) in
19
20
21 patients receiving CBDCA-based chemotherapy.
22
23
24

25 CBDCA is widely used against various cancers. The complete response (CR) rate (the
26
27 absence of emetic episodes and no use of rescue medication) for first generation 5-HT₃RA
28
29 and DEX varies depending on the cancer type; the rate is approximately 50% in patients with
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
gynecological cancer [4-5] and approximately 65% in those with thoracic cancer [6-7]. This
difference is due to the background of cancer types. Gynecological cancer patients are only
females and are younger than thoracic cancer patients. Female gender, younger age,
non-habitual alcohol intake and non-smoker etc. are known as risk factors for
chemotherapy-induced nausea and vomiting (CINV) [8]. Therefore, we believe NK₁RA with
high drug cost is unnecessary for CBDCA-based therapy in thoracic cancer patients.
Furthermore, because of the inhibition of cytochrome P450 3A4, clinically significant
pharmacokinetic interactions of aprepitant (APR) and fosaprepitant have been reported not only
general agents but also chemotherapy agents [9]. Therefore, the development of antiemetic

1
2
3
4 therapy without NK₁RA is beneficial in complicated cancer chemotherapy.
5
6

7 Olanzapine (OLZ) is classified as a multi-acting receptor-targeted antipsychotic and blocks
8
9
10 dopaminergic D₁, D₂, D₃, and D₄ receptors; serotonergic 5-HT_{2A}, 5-HT_{2B}, 5-HT₃, and 5-HT₆
11
12
13 receptors; histamine H₁ receptors; and muscarinic acetylcholine M₁, M₂, M₃, and M₄ receptors
14
15
16 [10]. Among its other uses, OLZ is used to improve CINV. Navari et al. performed a phase III
17
18
19 trial to confirm the superiority of 10mg OLZ combined with palonosetron (PALO) and DEX
20
21
22 to an antiemetic regimen consisting of PALO, DEX, and APR in highly emetogenic
23
24
25 chemotherapy (HEC). The study could not demonstrate that the OLZ regimen is superior to
26
27
28 the APR regimen. However, the CR rates for the acute, delayed, and overall period were not
29
30
31 significantly different between the OLZ regimen and the APR regimen. On the other hand, the
32
33
34 OLZ regimen showed excellent control of nausea in the delayed and overall period [11].
35
36
37 Moreover, in the United States and Asia, the effectiveness of a combination of 10 mg OLZ
38
39
40 and standard antiemetic therapy has been demonstrated for HEC in randomized control trials;
41
42
43 however, the resulting patient sedation due to the therapy may be a concern [12-15]. In Japan,
44
45
46 three phase II studies revealed the efficacy and safety of the combination of 5 mg OLZ and
47
48
49 standard triplet therapy for CINV induced by HEC [16-18]. In a trial, Yanai et al. reported that
50
51
52 OLZ at 5 mg and 10 mg showed comparable CR effects, but the 5 mg dose was less sedative
53
54
55 [18].
56
57

58 However, the effectiveness of OLZ against CBDCA-induced CINV has not been
59
60

1
2
3
4 demonstrated. The cost per treatment cycle of 5 mg of OLZ (brand: 733.60 JPY, generic:
5
6
7 180.80 JPY) is less than that of PALO (14851.00 JPY) or NK₁RA (APR: 11638.20 JPY,
8
9
10 fosaprepitant: 14545.00 JPY), and confirming the effectiveness of the combination use of
11
12
13 OLZ, first generation 5-HT₃RA, and DEX would change the standard antiemetic treatment for
14
15
16 CBDCA-based chemotherapy in thoracic cancer.

17
18
19 In recent years, immune checkpoint inhibitor (ICI) in combination with chemotherapy is
20
21
22 available in clinical settings for lung cancer. Arbour et al. reported that baseline corticosteroid
23
24
25 use was associated with poorer outcomes in patients who were treated with ICI [19].

26
27
28 Therefore, there is a concern that DEX as emesis prophylaxis may affect the effects of ICI
29
30
31 combination chemotherapy. The noninferiority of DEX sparing on day 2 and 3, combined
32
33
34 with PALO has been demonstrated for MEC in randomized control trials [20-22]. Therefore,
35
36
37 to use PALO can reduce corticosteroid. Among the ICI combination therapies, the
38
39
40 pembrolizumab combined with CBDCA and pemetrexed is one of the most often used
41
42
43 regimens for advanced non-small-cell lung cancer. In the KEYNOTE-189 trial that proved
44
45
46 the effectiveness of this regimen, for prophylaxis of cutaneous reaction, the administration of
47
48
49 DEX 8 mg per day for 2 days besides DEX of day 1 used for antiemetic therapy had been
50
51
52 regulated by the protocol [23]. Therefore, we plan to administer DEX for 3 days.

53
54
55 The efficacy of OLZ has been demonstrated in both combinations with the first and second
56
57
58 generation 5HT₃RA in HEC [11-18, 24]. Therefore, granisetron (GRN) was chosen as
59
60

1
2
3
4 5HT₃RA in the study.
5
6

7 Given the above, we plan this open-label, single-arm, multicenter, phase II trial to evaluate
8
9 the efficacy and safety of 5 mg olanzapine plus granisetron (GRN) and DEX in CBDCA
10
11 combination therapy with $AUC \geq 5$ mg/mL/min for the prevention of CINV in patients with
12
13 thoracic cancer.
14
15
16
17
18
19
20
21

22 **Study Protocol**

23
24
25
26
27

28 **Objective**

29
30 Our objective is to evaluate the efficacy and safety of 5 mg olanzapine plus GRA and DEX
31
32 for the prevention of nausea and vomiting during CBDCA combination therapy achieving
33
34 $AUC \geq 5$ mg/mL/min in patients with thoracic cancer. The study was approved by the
35
36 institutional review board at each participating center and was independently monitored by the
37
38 alliance data center and safety monitoring board.
39
40
41
42
43
44
45
46
47
48

49 **Study setting**

50
51 This study is an open-label, single-arm, multicenter, phase II trial conducted in four centers in
52
53 Japan.
54
55
56
57
58
59
60

End points

We choose the CR rate as the primary endpoint, defined as the absence of emetic episodes and no use of rescue medication during the overall assessment period (0–120 h) after the initiation of CBDCA.

Secondary endpoints are the CR rate at the early assessment period (0–24 h), the CR rate at the delayed assessment period (25–120 h), and the complete control rate defined as no significant nausea, no emetic episodes, and no use of rescue medication for the acute, delayed, and overall assessment periods. We use a four-grade categorical scale (none, mild, moderate, or severe) to stratify nausea and choose the moderate and severe categories to define significant nausea. The total control rate is defined as the absence of nausea and emetic episodes and no use of rescue medication for the acute, delayed, and overall assessment periods. The time to treatment failure is defined as the time to the first emetic episode or the use of rescue medication. The levels of nausea, anorexia, sleepiness, impact on life severity, and patient satisfaction with antiemetic therapy are also classified using a four-grade categorical scale. These data are collected from patient diaries. Adverse events are graded according to the CTCAE version 4.0.

Eligibility criteria

Inclusion criteria

- (i) Patients with thoracic cancer scheduled to receive CBDCA-based chemotherapy ($AUC \geq 5$)
- (ii) Age, 20–79 years at registration

1
2
3
4 (iii) Eastern Cooperative Oncology Group performance status of 0, 1, or 2
5
6

7 (iv) Absence of symptomatic brain metastasis and carcinomatosis
8
9

10 (v) Absence of a history of the administration of moderate-to-high emetogenic chemotherapy
11
12

13 (vi) No current use of any drug with antiemetic activity or inducing somnolence, such as
14
15 5-HT₃RA, NK₁RA, corticosteroids, dopamine receptor antagonists, phenothiazine
16
17 tranquilizers, antihistamine drugs (paclitaxel administration allowed during premedication),
18
19 and benzodiazepine agents
20
21
22
23

24 (vii) Meeting the following standard values of general clinical tests:
25
26

27 (a) aspartate aminotransferase $\leq 100\text{U/L}$
28
29

30 (b) alanine aminotransferase $\leq 100\text{U/L}$
31
32

33 (c) total bilirubin $\leq 2.0\text{ mg/dL}$
34
35
36

37 (viii) Patients who provided written informed consent
38
39
40
41
42

43 **Exclusion criteria**

44
45

46 (i) History of hypersensitivity or allergy to study drugs or similar compounds
47
48

49 (ii) Antiemetics needed at the time of enrollment
50
51

52 (iii) Started opioid intake in the 48 h prior to enrollment
53
54

55 (iv) Presence of unstable angina, ischemic heart disease, cerebral hemorrhage or apoplexy, or
56
57 active gastric or duodenal ulcer within 6 months prior to enrollment
58
59
60

- 1
2
3
4 (v) Presence of convulsive disorders requiring anticonvulsants therapy
5
6
7 (vi) Presence of ascites effusion requiring paracentesis
8
9
10 (vii) Presence of gastrointestinal obstruction
11
12
13 (viii) Breastfeeding or pregnant women or those not willing to use contraception
14
15
16 (ix) Presence of psychosis or psychiatric symptoms that interfere with daily life
17
18
19 (x) Abdominal or pelvic irradiation within 6 days prior to enrollment
20
21
22 (xi) Presence of diabetes mellitus
23
24
25 (xii) Being a habitual smoker at the time of enrollment
26
27
28 (xiii) Patients deemed inappropriate for the study by the investigator (From daily behavior,
29
30 patients who may not be able to keep medication adherence and/or fulfill patient diary etc.)
31
32
33
34
35
36

37 **Registration**

38
39
40 The accrual started in February 2018.
41
42
43
44
45

46 **Treatment methods**

47
48 The study antiemetics administrations are shown in Table 1. All patients receive GRA (1 mg
49 intravenous infusion on day 1, 30 min before chemotherapy), DEX (9.9 mg intravenous
50 infusion or 12 mg oral administration on day 1, 30 min before chemotherapy, and 6.6 mg
51 intravenous infusion or 8 mg oral administration on days 2–3), and OLZ (5 mg oral
52 administration on days 1–4, after supper). In addition, when paclitaxel is used, DEX is
53 administered at 19.8 mg intravenously or 20 mg orally on day 1. Dexamethasone injection is
54
55
56
57
58
59
60

1
2
3
4 provided as dexamethasone sodium phosphate. The 8 mg of dexamethasone sodium
5
6 phosphate contains 6.6 mg of dexamethasone.
7
8
9

10 11 **Follow up**

12
13
14 We schedule physical and blood examinations of patients before the initiation of treatment
15
16 and once between days 5 and 15 after treatment initiation. The data are collected from patient
17
18 diaries. Patients are required to fill the diary for every 24 h from the start of chemotherapy to
19
20 120 h periods. After the overall assessment period (0–120 h), patient-reported study diaries
21
22 are collected (figure 1. provides details of the schedule of enrollment, interventions, and
23
24 assessments).
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Study design and statistical methods**

39
40 The hypothesis of this study is that the CR rate for 5 mg olanzapine plus GRA and DEX
41
42 during CBDCA combination therapy achieving $AUC \geq 5$ mg/mL/min will be significantly
43
44 higher than that for standard antiemetic doublet therapy.
45
46
47

48
49 Other trials have shown CR rates of approximately 65% [6, 7]. An improvement of the
50
51 treatment effect has to be >10% to amend the guideline of the MASCC/ESMO2016 [2]
52
53 according to previous studies in which the CR ratio of antiemesis treatment by PALO, DEX,
54
55 and APR was 80.5%–92% [25-27]. We think an improvement of >15% in the CR rate can be
56
57 clinically meaningful.
58
59
60

1
2
3
4 Therefore, assuming a null hypothesis of the CR rate to be $\leq 65\%$ and an alternative
5
6
7 hypothesis to be 80% , we calculate that a minimum of 48 patients are required to achieve a
8
9
10 one-sided type I error of 0.1 and 80% of power based on the exact binomial distribution.
11
12
13 Because some dropouts are expected, we set the target sample size at 50. A sample size
14
15
16 calculation was performed by SAS 9.4 (Cary, NC, USA).
17
18
19
20
21

22 **Patient and Public Involvement**

23
24
25 Patients and/or public were not involved in the design of this study.
26
27
28
29
30

31 **Ethics and dissemination**

32
33
34 The study protocol was approved by the institutional review board at each of the participating
35
36
37 centers. A signed informed consent form is obtained from all patients before enrollment. Data
38
39
40 will be presented at international conferences and published in peer-reviewed journals.
41
42
43
44
45

46 **University hospital medical information network (UMIN) registration**

47
48
49 This study protocol was registered at the UMIN Clinical Trial Registry (UMIN-CTR) on
50
51
52 February 14, 2018, as UMIN000031267 (<http://www.umin.ac.jp/ctr/index-j.htm>).
53
54
55
56
57

58 **Participating institutions**

1
2
3
4 Gifu University Hospital, Gifu Municipal Hospital, Murakami Memorial Hospital Asahi
5
6
7 University, and Gunma Prefectural Cancer Center.
8
9
10
11
12

13 **Trial status**

14
15
16 February 2018: protocol approval by the Ethics Committee.
17

18
19 February 2018: Start of inclusion.
20

21
22 December 2019: End of inclusion.
23

24
25 We will submit the manuscript during the first half of 2020.
26
27
28
29
30

31 **Funding statement**

32
33
34 This work is supported by self-funding from the Department of Cardiology and Respiriology
35
36
37 at the Gifu University Graduate School of Medicine.
38
39

40 **Competing interests statement**

41
42
43 None declared.
44
45
46
47
48

49 **Authors' contributions**

50
51
52 HI, MS, TG, YF, and YO made a significant contribution to the conception and design of the
53
54
55 study protocol. MS provided statistical expertise. The protocol was written by HI, MS, TG,
56
57
58 YF, TY, NF, KM, DK, TO, MY, and CH and critically reviewed by AS, and YO. HI, MS,
59
60

1
2
3
4 TG, and YF drafted the manuscript. All the authors read and approved the final paper.
5
6
7
8
9

10 **References**

- 11
12
13 1. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for
14
15 the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of
16
17 nausea and vomiting in advanced cancer patients. *Ann Oncol* 2016;27 Suppl 5: v119–33.
18
19
20
21
- 22 2. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical
23
24 Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017; 35:3240–61.
25
26
27
- 28 3. NCCN clinical practice guidelines in oncology: Antiemesis Version 2.2017. Available
29
30 from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
31
32
33
- 34 4. Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebo-controlled, double-blind
35
36 study of aprepitant in nondrinking women younger than 70 years receiving moderately
37
38 emetogenic chemotherapy. *Br J Cancer* 2013; 109:859–65.
39
40
41
42
- 43 5. Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of
44
45 chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy
46
47 regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients
48
49 with gynecologic cancer receiving paclitaxel and carboplatin. *Int J Clin Oncol* 2016;
50
51 21:491–7.
52
53
54
55
- 56 6. Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell
57
58
59
60

- 1
2
3
4 lung cancer receiving carboplatin-based chemotherapy. *Lung Cancer* 2014; 84:259–64.
5
6
7 7. Endo J, Iihara H, Yamada M, et al. A randomized controlled non-inferiority study
8
9
10 comparing the antiemetic effect between intravenous granisetron and oral azasetron based
11
12
13 on estimated 5-HT₃ receptor occupancy. *Anticancer Res* 2012; 32:3939–47.
14
15
16 8. Sekine I, Segawa Y, Kubota K, et al. Risk factors of chemotherapy-induced nausea and
17
18
19 vomiting: index for personalized antiemetic prophylaxis. *Cancer Sci* 2013; 104:711–7.
20
21
22 9. Patel P, Leeder JS, Piquette-Miller M, et al. Aprepitant and fosaprepitant drug
23
24
25 interactions: a systematic review. *Br J Clin Pharmacol*. 2017; 83:2148–2162.
26
27
28 10. Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced
29
30
31 nausea and vomiting. *J Adv Pract Oncol* 2014; 5:24–9.
32
33
34 11. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of
35
36
37 chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J Support*
38
39
40 *Oncol* 2011;9:188–95.
41
42
43 12. Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant
44
45
46 for the prevention of concurrent chemotherapy radiotherapy-induced nausea and
47
48
49 vomiting. *J Community Support Oncol* 2016; 14:141–7.
50
51
52 13. Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriappa L, et al. The efficacy, safety,
53
54
55 and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: A
56
57
58 pilot study from south India. *Chemother Res Pract* 2016; 2016:3439707.
59
60

- 1
2
3
4 14. Wang X, Wang L, Wang H, Zhang H. Effectiveness of olanzapine combined with
5
6
7 ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small
8
9
10 cell lung cancer. *Cell Biochem Biophys* 2015; 72:471–3.
11
- 12
13 15. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of
14
15
16 chemotherapy-induced nausea and vomiting. *N Engl J Med* 14; 375:134–42.
17
- 18
19 16. Abe M, Hirashima Y, Kasamatsu Y, et al. Efficacy and safety of olanzapine combined
20
21
22 with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting
23
24
25 induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase
26
27
28 II trial. *Support Care Cancer* 2016; 24:675–82.
29
- 30
31 17. Nakashima K, Murakami H, Yokoyama K, et al. A Phase II study of palonosetron,
32
33
34 aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based
35
36
37 chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. *Jpn J*
38
39
40 *Clin Oncol* 2017; 47:840–3.
41
- 42
43 18. Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding
44
45
46 study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly
47
48
49 emetogenic cisplatin-based chemotherapy. *Int J Clin Oncol* 2018; 23:382–8.
50
- 51
52 19. Arbour KC, Mezquita L, Long N, et al. Impact of Baseline Steroids on Efficacy of
53
54
55 Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With
56
57
58 Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2018 ; 36:2872-2878
59
60

- 1
2
3
4 20. Aapro M, Fabi A, Nolè F, et al. Double-blind, randomised, controlled study of the
5
6 efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without
7
8 dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by
9
10 moderately emetogenic chemotherapy. *Ann Oncol*. 2010; 21:1083-8.
11
12
13
14
15
16 21. Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day
17
18 dexamethasone for prevention of nausea and vomiting following moderately emetogenic
19
20 chemotherapy: a randomized, multicenter, phase III trial. *Support Care Cancer*. 2011;
21
22 19:1217-25.
23
24
25
26
27
28 22. Komatsu Y, Okita K, Yuki S, et al. Open-label, randomized, comparative, phase III study
29
30 on effects of reducing steroid use in combination with Palonosetron. *Cancer Sci*. 2015;
31
32 106:891-5.
33
34
35
36
37 23. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in
38
39 Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018; 378:2078-2092.
40
41
42
43 24. Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of
44
45 chemotherapy-induced nausea and vomiting. *J Exp Clin Cancer Res*. 2009; 28:131.
46
47
48
49 25. Kitazaki T, Fukuda Y, Fukahori S, et al. Usefulness of antiemetic therapy with aprepitant,
50
51 palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or
52
53 carboplatin-based chemotherapy. *Support Care Cancer* 2015; 23:185–90.
54
55
56
57
58 26. Kusagaya H, Inui N, Karayama M, et al. Evaluation of palonosetron and dexamethasone
59
60

1
2
3
4 with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients
5
6
7 with advanced non-small-cell lung cancer. Lung Cancer 2015; 90:410–6.
8
9

- 10 27. Miya T, Kobayashi K, Hino M, et al. Efficacy of triple antiemetic therapy (palonosetron,
11
12 dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients
13
14 receiving carboplatin-based, moderately emetogenic chemotherapy. Springerplus 2016;
15
16
17
18
19 5:2080.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Antiemetic administrations

Antiemetics		day1	day2	day3	day4
granisetron	i.v.	1mg			
dexamethasone	p.o.	12mg*	8mg	8mg	
or					
dexamethasone	i.v.	9.9mg*	6.6mg	6.6mg	
olanzapine	p.o.	5mg	5mg	5mg	5mg

*When paclitaxel is used, on day 1 DEX is administered 19.8 mg intravenously or 20 mg orally.

Figure 1. The schedule of enrolment, interventions, and assessments

	Enrolment	Enrolment	Post- Enrolment					
TIMEPOINT	-8 days	0	day1	day2	day3	day4	day5	day6
ENROLMENT:								
Eligibility screen	X							
History and physical	X							
ECOG PS	X							
Laboratory studies	X							X
Informed consent	X							
Enrolment		X						
INTERVENTIONS:								
<i>Antiemetic administrations</i>			←————→					
ASSESSMENTS:								
<i>Patient diaries</i>		X	X	X	X	X	X	X
<i>Adverse events</i>		X	X	X	X	X	X	X
<i>Patient related factor survey</i>								X
<i>Patient satisfaction</i>								X



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	12
	2b	All items from the World Health Organization Trial Registration Data Set	12
Protocol version	3	Date and version identifier	12
Funding	4	Sources and types of financial, material, and other support	12
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	13
	5b	Name and contact information for the trial sponsor	1, 13
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	none
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	7

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	5, 6
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	11
7				
8	Objectives	7	Specific objectives or hypotheses	7
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	7
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	12
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	8, 9
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	10
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	10, 11
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	10, 11
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	10, 11
32				
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	7, 8
35			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
36			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
37			efficacy and harm outcomes is strongly recommended	
38				
39				
40	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	18
41			participants. A schematic diagram is highly recommended (see Figure)	
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	12
5				
6				
7	Methods: Assignment of interventions (for controlled trials)			
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	single arm
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	single arm
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	single arm
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	non- blinded
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	non- blinded
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	17
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	10, 11
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	no plans
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	7
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	no interim analysis
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	10, 11
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	no plans
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	12
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	12
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	no plans
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	13
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	7
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	none
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	12
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	13
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	none
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	9
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	none
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.